WASHINGTON — The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines the Trump administration deems as “supporting U.S. national interests.”

The nine medicines announced by the FDA include potential treatments for vaping addiction, deafness, pancreatic cancer and other conditions.

Several of the drugs would compete with higher-priced drugs already on the U.S. market.

At the White House, President Donald Trump highlighted the injectable infertility drug, Pergoveris, which is currently sold in Europe for patients going through IVF treatments. Trump said FDA approval of the drug in the U.S. would help lower IVF costs for American families, one of his

See Full Page